









市场行情
/
股票
/
nasdaq-regn
/

再生元制药

REGN

749.790USD

+3.430+0.46%

收盘 12/17, 16:00（美东）报价延迟15分钟

78.95B总市值

17.29市盈率 TTM



再生元制药

749.790

+3.430+0.46%

概览公司财务分析

概览

公司

财务

分析

关于再生元制药公司

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

再生元制药简介



公司代码REGN

公司名称Regeneron Pharmaceuticals Inc

上市日期Apr 02, 1991

CEOSchleifer (Leonard S)

员工数量15106

证券类型Ordinary Share

年结日Apr 02

公司地址777 Old Saw Mill River Road

城市TARRYTOWN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编10591

电话17813705000

网址https://www.regeneron.com/

公司代码REGN

上市日期Apr 02, 1991

CEOSchleifer (Leonard S)

再生元制药公司高管



名称

名称/职务

职务

持股

持股变动

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

56.41K

+3.71%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

44.85K

+2.47%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

37.73K

+5.04%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

21.78K

+10.31%

Mr. Arthur F. (Art) Ryan

Independent Director

17.66K

-0.10%

Ms. Marion E. McCourt

Executive Vice President - Commercial

15.51K

+7.93%

Dr. Michael S. Brown, M.D.

Independent Director

12.62K

-0.13%

名称

名称/职务

职务

持股

持股变动

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

56.41K

+3.71%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

44.85K

+2.47%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

37.73K

+5.04%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Sanofi

1.44B

39.28%

EYLEA

754.30M

20.52%

Bayer

415.00M

11.29%

EYLEA HD

393.20M

10.70%

Libtayo

247.80M

6.74%

其他

421.70M

11.47%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

Sanofi

1.44B

39.28%

EYLEA

754.30M

20.52%

Bayer

415.00M

11.29%

EYLEA HD

393.20M

10.70%

Libtayo

247.80M

6.74%

其他

421.70M

11.47%

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

8.71%

BlackRock Institutional Trust Company, N.A.

5.29%

State Street Investment Management (US)

4.54%

Dodge & Cox

4.41%

JP Morgan Asset Management

2.85%

其他

74.20%

持股股东

占比

The Vanguard Group, Inc.

8.71%

BlackRock Institutional Trust Company, N.A.

5.29%

State Street Investment Management (US)

4.54%

Dodge & Cox

4.41%

JP Morgan Asset Management

2.85%

其他

74.20%

股东类型

持股股东

占比

Investment Advisor

45.11%

Investment Advisor/Hedge Fund

30.91%

Hedge Fund

5.04%

Pension Fund

2.69%

Research Firm

2.61%

Bank and Trust

2.25%

Individual Investor

2.06%

Sovereign Wealth Fund

1.23%

Insurance Company

0.20%

其他

7.90%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

2596

94.26M

91.26%

-4.21M

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

2023Q2

2360

99.25M

92.00%

-1.42M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

9.37M

+14.55K

+0.16%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.67M

5.44%

-75.61K

-1.32%

Jun 30, 2025

State Street Investment Management (US)

4.83M

4.64%

+42.34K

+0.88%

Jun 30, 2025

Dodge & Cox

3.83M

3.67%

+1.50M

+64.64%

Jun 30, 2025

JP Morgan Asset Management

2.82M

2.7%

-1.26M

-30.95%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.47M

2.37%

-4.53K

-0.18%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

2.17M

2.09%

-7.70K

-0.35%

Aug 31, 2025

Putnam Investment Management, L.L.C.

2.03M

1.95%

+116.30K

+6.08%

Jun 30, 2025

Capital World Investors

1.97M

1.89%

+27.38K

+1.41%

Jun 30, 2025

Loomis, Sayles & Company, L.P.

1.94M

1.86%

+305.09K

+18.65%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

ProShares Ultra Nasdaq Biotechnology

6.6%

Invesco Nasdaq Biotechnology ETF

6.55%

Amplify Weight Loss Drug & Treatment ETF

6.4%

iShares Biotechnology ETF

5.9%

Simplify Health Care ETF

5.54%

VanEck Biotech ETF

5.51%

Invesco Biotechnology & Genome ETF

5.4%

iShares Genomics Immunology and Healthcare ETF

4.97%

First Trust NASDAQ Pharmaceuticals ETF

4.36%

First Trust NYSE Arca Biotechnology Index Fund

3.88%

ProShares Ultra Nasdaq Biotechnology

占比6.6%

Invesco Nasdaq Biotechnology ETF

占比6.55%

Amplify Weight Loss Drug & Treatment ETF

占比6.4%

iShares Biotechnology ETF

占比5.9%

Simplify Health Care ETF

占比5.54%

VanEck Biotech ETF

占比5.51%

Invesco Biotechnology & Genome ETF

占比5.4%

iShares Genomics Immunology and Healthcare ETF

占比4.97%

First Trust NASDAQ Pharmaceuticals ETF

占比4.36%

First Trust NYSE Arca Biotechnology Index Fund

占比3.88%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

再生元制药的前五大股东是谁？



再生元制药的前五大股东如下：
The Vanguard Group, Inc.持有股份：9.37M，占总股份比例：9.00%。
BlackRock Institutional Trust Company, N.A.持有股份：5.67M，占总股份比例：5.44%。
State Street Investment Management (US)持有股份：4.83M，占总股份比例：4.64%。
Dodge & Cox持有股份：3.83M，占总股份比例：3.67%。
JP Morgan Asset Management持有股份：2.82M，占总股份比例：2.70%。